Thermo Fisher to drop $1.7B on gene therapy maker Brammer Bio

Thermo Fisher (NYSE:TMO) said today that it will acquire gene and cell therapy manufacturer Brammer Bio for $1.7 billion in cash.

Brammer Bio is a viral vector contract developer and manufacturer of gene therapies and gene-modified cell therapies for biopharma customers. The Cambridge, Mass.-based business has nearly 600 employees at primary locations in Massachusetts and Alachua, Fla.

Get the full story on our sister site, Medical Design & Outsourcing.

The post Thermo Fisher to drop $1.7B on gene therapy maker Brammer Bio appeared first on MassDevice.

from MassDevice https://ift.tt/2HFUBN4